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Abstract 
 
Natural killer (NK) cells expressing NKG2C and CD57 expand following human 
cytomegalovirus (CMV) infection. This NK cell subset downregulates FcεR1γ and 
acquires enhanced capacity to mediate antibody-dependent cellular cytotoxicity (ADCC). 
Expansion of these differentiated NK cells is exaggerated in human immunodeficiency 
virus (HIV) infection. Individuals lacking the gene encoding NKG2C have diminished 
resistance to HIV, but it remains unclear whether differentiation into NK cells with 
superior ADCC is impaired in NKG2C
null
 individuals. Therefore, our objective was to 
investigate if CMV-driven NK cell differentiation into enhanced killers is impaired in 
NKG2C
null
 HIV-infected individuals. Phenotypic (CD57
+, FcεR1γ-) and functional (IFN-
γ, TNF-α induction and cytotoxicity) NK cell responses were compared between 
NKG2C
null
 and matched NKG2C-expressing individuals by flow cytometry following 
stimulation through natural cytotoxicity receptors (using K562 cells) or CD16 (using 
monoclonal antibody, 3G8). Cytotoxicity was measured in 
51
Chromium release assays 
against anti-CD16-coated P815 cells (redirected lysis) and anti-human leukocyte antigen 
(HLA) class I antibody-coated C1R cells (classical ADCC). Antibodies were titrated to 
determine concentrations producing half maximal responses (EC50) to compare 
sensitivity. Our data indicate highly similar CMV-driven NK cell differentiation in terms 
of both general phenotype and function, regardless of NKG2C genotype. The observed 
equivalency between groups suggests alternate routes of CMV-driven NK cell 
differentiation, which are independent of NKG2C. 
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Chapter 1: Introduction 
1.1 Natural Killer Cells 
Natural killer (NK) cells comprise 10-15% of the human lymphocyte population 
and act as a primary line of defense against pathogens
1
. These large granular lymphocytes 
represent a branch of the innate immune system and are able to kill infected, transformed, 
or otherwise stressed cells by targeted release of perforin and granzymes
2
. NK cells also 
release pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and 
interferon gamma (IFN-γ), in response to aberrant cells. These cytokines help coordinate 
adaptive branches of host immunity to begin mounting a response
3
. 
NK cells are classically defined by expression of CD56 and absence of CD3
4
. 
Within this population, NK cells can be further subdivided into CD56
bright
 and CD56
dim
 
groups.  The former NK cell population displays enhanced production of cytokines and 
diminished cytotoxic capacity in comparison to the more highly differentiated CD56
dim
 
NK cells, which are more likely to express CD57 (a marker of maturation)
5
. CD56
dim
 
CD57
+
 NK cells have high levels of surface CD16 expression and degranulate 
exceptionally well following stimulation through this receptor
5
. 
NK cells have common features with cells of the adaptive immune system, such as 
similar ontogeny
6
. For example, like B and T lymphocytes, NK cells arise from common 
lymphoid progenitor cells
7
. However, whereas B and T cells undergo somatic 
recombination to create immense receptor diversity, NK cells have a relatively limited 
repertoire of germline encoded receptors
8
. These receptors transduce either activating or 
inhibitory signals upon phosphorylation of immunoreceptor tyrosine-based activating 
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(ITAM) or inhibitory (ITIM) motifs on signaling proteins
9
. This results in NK cell-
mediated killing, or activation-related cytokine release, only when the balance of 
activating receptor stimulation outweighs inhibitory signaling (see Section 1.1.4)
6
.  
1.1.2 Inhibitory NK Cell Receptors 
If an NK cell receives equal stimulation through activating and inhibitory 
receptors, inhibitory signaling dominates. A major form of NK cell inhibitory signaling 
arises from killer cell immunoglobulin-like receptors (KIRs), which are characterized by 
either two (KIR2D) or three (KIR3D) extracellular Ig-like domains
10
. The inhibitory 
subset of KIRs recognize various human leukocyte antigen (HLA) class I molecules, have 
long (L) cytoplasmic tails, and associate with ITIMs
11
. Other important inhibitory NK cell 
receptors include leukocyte immunoglobulin-like receptor-1 (LIR-1), which recognizes a 
broad range of HLA class I molecules, and NKG2A/KLRD-1 (CD159a/CD94), which 
belongs to the C-type lectin-like family, forms a heterodimer with CD94, and transfers an 
inhibitory signal upon binding of HLA-E
12,13
. All of the inhibitory signals resulting from 
ligation of these receptors are transduced to the NK cell via the phosphorylation of 
tyrosine residues on ITIMs, which in turn recruit tyrosine phosphatases, Src homology 
region 2 domain-containing phosphatase (SHP) 1 and 2. See Table 1.1 for a list of 
inhibitory receptors and their ligands.  
1.1.3 Activating NK Cell Receptors 
NK cells are triggered to kill through ligation of activating receptors which 
transduce activating signals through the phosphorylation of ITAMs
14
. Upon 
phosphorylation, ITAMs recruit kinases that propagate activating signals. KIRs can be  
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Table 1.1 Inhibitory NK Cell Receptors 
Receptor Associated motifs Ligand(s) 
Inhibitory KIRs (except 
KIR2DL5 and 3DL3) 
ITIMs HLA class I 
molecules 
LIR-1 ITIMs HLA class I 
molecules 
NKG2A   ITIMs HLA-E 
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activating in nature if they associate with ITAMs instead of ITIMS. Numerous activating 
KIRs have undefined ligands and are thought to have evolved from inhibitory KIRs
15
. 
These activating KIRs have short (S) cytoplasmic tails, with the exception of KIR2DL4, 
which contains a long cytoplasmic tail despite transducing activating signals
16
. Activating 
and inhibitory KIRs are often highly homologous in their extracellular domains which 
makes differentiation using monoclonal antibodies (mAbs) challenging
17
. 
Natural cytotoxicity receptors (NCRs) are most often responsible for NK cell 
activation and these receptors include NKp46, 44, 30, and 80. NKp46 recognizes 
influenza hemagglutinin (HA) and parainfluenza HA-neuraminidase and is considered the 
main activating NK cell receptor
18
.  Other NCRs and their ligands are summarized in 
Table 1.2. NKG2C/KLRD-1 (CD159c/CD94) is another important activating receptor 
which belongs to the C-type lectin-like family, forms a heterodimer with CD94, and 
associates with DNAX-activating protein of 12 kDa (DAP12), a transmembrane signaling 
protein which contains an ITAM
13
. Similar to NKG2A, NKG2C binds to cell surface 
HLA-E, but with lower affinity
19
. Expression of the activating receptor NKG2C and the 
inhibitory receptor NKG2A is thought to be mutually exclusive
18
. NKG2D is a 
homodimer which also belongs to the C-type lectin-like receptor family, however, it 
associates with the transmembrane signaling protein DNAX-activating protein of 10 kDa 
(DAP10)
20
. Ligation of NKG2D by major histocompatibility complex class I chain-
related (MIC) molecules MICA, MICB, or UL16-binding protein 1 (ULBP1) results in 
NK cell activation
21
. 
The activating NK cell receptor which is most pertinent to our upcoming 
discussion of NK cell function is FcγRIIIa (CD16a), the low affinity IgG receptor present 
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on virtually all CD56
dim
 NK cells
22
. This receptor comes in two forms, CD16a and 
CD16b, however, only the former receptor is expressed on NK cells and will herein be 
referred to as CD16
23
. Two signaling adaptor molecules associate as a heterodimer with 
CD16 in the transmembrane region, CD3ζ, which contains three ITAMs, and FcεR1γ, 
which contains one ITAM
9,24
. CD16, also known as the immunoglobulin fragment 
crystallizable (Fc) receptor, is essential for NK cell-mediated antibody-dependent cellular 
cytotoxicity (ADCC), a critical defense against viral invasion
25
. See Table 1.2 for a list of 
activating receptors and their ligands. 
1.1.4 NK Cell-Mediated Killing 
As mediators of innate immunity, NK cells are capable of lysing aberrant cells 
without prior sensitization
26
. The exocytosis of secretory granules containing perforin and 
granzymes is responsible for NK cell-mediated killing
2
. These lysosomes are readily 
available for targeted release toward aberrant cells – hence the appropriately named 
“natural killer” cell. Target cell lysis is mediated by perforin, which forms pores in the 
target cell membrane, leading to osmotic shock
27
.  These perforin-mediated pores also 
allow granzymes into the cytosol, wherein granzymes A and B facilitate the cleavage of 
caspases, resulting in programmed cell death
28
. Perforin and granzyme-mediated killing 
only occurs when activating signaling outweighs the inhibitory signaling from NK cell 
interactions with a target cell. 
NK cell-mediated lysis through direct interaction between an NK cell and a target 
cell is referred to as natural cytotoxicity
29
. NK cells are also triggered to kill through the 
crosslinking of an antigen-specific antibody to the target cell through the ligation of  
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Table 1.2 Activating NK Cell Receptors 
Receptor Adaptor molecules Ligand(s) 
KIR2DS2/2DS5 DAP12 Unknown 
KIR2DS1 DAP12 HLA-C 
KIR2DL4 FcɛR1γ HLA-G 
KIR3DS1 DAP12 HLA-F 
NKp46 CD3ζ and FcɛR1γ Viral HA 
NKp30 CD3ζ and FcɛR1γ B7-H6, Cytomegalovirus pp65, HLA-
B associated transcript 3 (BAT3) 
NKp44 DAP12 Viral HA 
NKG2C DAP12 HLA-E 
NKG2D DAP10 MICA/MICB/ULBP1 
CD16 CD3ζ and FcεR1γ IgG 
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CD16, referred to as ADCC
29
. This takes non-pathogen-specific NK cell-mediated killing 
and renders it specific by harnessing the pathogen-specificity of antibodies to tag aberrant 
cells for lysis. Both natural cytotoxicity and ADCC are more potent if an NK cell 
expresses at least one self-specific inhibitory KIR. This effect is a result of classical NK 
cell licensing
30
. 
1.1.5 Classical NK Cell Licensing 
Licensing refers to a maturation process wherein cells become fully competent in 
their functional role. During classical NK cell licensing, inhibitory KIRs are involved in 
assuring the NK cell can differentiate a healthy cell from an aberrant cell by engaging 
with self-major histocompatibility complex (MHC) class I molecules. The MHC complex 
refers to a set of proteins which bind and present peptides derived from self or pathogens 
and are recognized by T lymphocytes (T cells) and NK cells
31
. In humans, the MHC 
complex is referred to as the HLA complex. Engagement of inhibitory KIRs with either 
HLA A, B, or C (class I) molecules results in the transduction of inhibitory signals to the 
NK cell. HLA class I molecules serve as excellent “self” markers to avoid NK cell killing 
because they are expressed on almost all human cells
32
.  
Lack of engagement between inhibitory KIRs and HLA class I molecules during 
development results in hyporesponsive NK cells
33
. If a host cell is altered in a way that 
downregulates HLA class I expression, such as through viral invasion, NK cells lack the 
inhibitory stimulus necessary to suppress killing. Evidence for the presence of activating 
receptors on host cells came about in an experiment wherein NK cells were able to kill 
HLA class I-deficient target cells. This display of immunosurveillance is explained by the 
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“missing-self hypothesis”, wherein infected or tumor cells, which evade T cell defenses 
by downregulating MHC class I, are recognized by NK cells
34
.  
1.1.6 NK Cell Stimulation Assays 
A common experimental system to measure NK cell natural cytotoxicity is 
through incubation of peripheral blood mononuclear cells (PBMC) with natural NK cell 
targets. K562 cells are derived from immortalized human myelogenous leukemia cells 
and serve as natural NK cell targets due to their deficiency in HLA class I molecules. 
Stimulation through natural cytotoxicity receptors is mostly responsible for NK cell 
activation in this assay, resulting in K562 cell lysis, as well as pro-inflammatory cytokine 
expression. Intracellular expression of pro-inflammatory cytokines or surface expression 
of the degranulation marker, CD107a, is frequently measured by flow cytometry in these 
assays. Another way to measure NK cell activation is by 
51
Chromium (Cr)-labeling target 
K562 cells before incubation with PBMC, and measuring 
51
Cr release in supernatants 
post-incubation. The latter method was considered the gold standard for measuring NK 
cell killing, however, it comes with limitations
35
. 
51
Chromium release assays (CRAs) 
involve hazardous radioactive materials and do not allow for the distinction of NK cell 
subsets involved, whereas flow cytometry allows the measurement of variegated 
responses among specific cell subsets by sorting based on expression profiles.  
Another way to model NK cell activation is through the addition anti-CD16 
monoclonal antibodies, such as 3G8, which directly stimulate NK cells. This type of 
activation is referred to as antibody-dependent NK cell activation. Intracellular expression 
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of pro-inflammatory cytokines or degranulation markers post stimulation using flow 
cytometric analysis is a common way to measure NK cell activation in this assay. 
1.1.7 Pro-inflammatory cytokines 
NK cells respond to activation signals by producing cytokines, which enable 
intercellular communication between cells of the immune system. The resulting “cytokine 
milieu” is important for the development of adaptive immune defenses and is comprised 
mostly of TNF-α and IFN-γ36. Although CD56bright NK cells have enhanced production of 
pro-inflammatory cytokines, our discussion focuses mainly on CD56
dim
 NK cells, which 
are also able to produce cytokines after stimulation through activating or cytokine 
receptors
37
.  
IFN-γ is secreted primarily by T-helper1 CD4
+
 T cells, CD8
+
 T cells, and NK 
cells
38
. There are many ways in which IFN-γ is able to interfere with viral replication, 
such as upregulating MHC I and MHC II expression, and subsequently allowing 
heightened presentation of viral proteins. IFN-γ also activates macrophages, causes 
vasodilation, and further induces production of pro-inflammatory cytokines from other 
immune cells
38
. TNF-α is known for causing necrosis of tumor cells, but contributes to 
host defense by generating inflammation
39
. The production of IFN-γ and TNF-α by NK 
cells is important for overall host defense and is used to mark activated NK cells. 
Individuals with complete NK cell deficiencies lack NK cell-mediated cytolysis as 
well as the accompanying pro-inflammatory cytokine responses. These individuals, 
although extremely rare, are highly susceptible to certain infectious agents, such as 
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herpesviruses
4
. For the next section we will focus on cytomegalovirus (CMV), a beta-
herpesvirus which elicits a profound immune response, even in healthy individuals. 
1.2 Overview of Human Cytomegalovirus 
Human cytomegalovirus (CMV) is a double stranded DNA beta-herpesvirus that 
establishes a persistent, lifelong, and primarily latent infection
40
. CMV is the largest 
human herpes virus and has coevolved with its host for millions of years
41
. Primary 
infection with CMV occurs through contact with infected body fluids such as semen, 
vaginal secretions, breast milk, urine, and saliva
42
. Although mucosal epithelial cells 
serve as primary targets, endothelial cells, smooth muscle cells, dendritic cells (DC), 
fibroblasts and leukocytes are also permissive to CMV infection
43
.  
Primary infection, reactivation or de novo reinfection with CMV results in 
extensive transcription of the viral genome, compared to a more restricted transcriptional 
profile during CMV latency 
44
. Reactivations are generally controlled by a robust immune 
response in healthy hosts and, therefore, remain asymptomatic
45
. Conversely, in 
immunocompromised individuals, active infection can cause serious health 
complications.
46
. The most common populations at risk for CMV-related complications 
are transplant recipients, those co-infected with human immunodeficiency virus (HIV), 
and developing fetuses following congenital transmission
47
. The deleterious 
consequences of CMV infection among immunocompromised adults include serious end-
organ diseases, whereas newborns display symptoms such as hearing loss and 
neurodevelopmental delays
48,49
.  Even healthy hosts are not spared from the effects of 
CMV. In a process termed “memory inflation”, the immune system becomes highly 
 - 11 - 
preoccupied CMV and slowly dedicates an inordinate fraction of immune cells to its 
control. This can be seen in the overwhelming responses from both adaptive and innate 
branches of the human immune system
50
. 
1.2.1 CMV & Adaptive Immunity 
       1.2.1.1 Humoral Immunity 
The adaptive immune system mounts a dramatic CMV-specific response within 
both its cellular and humoral arms. CMV-infected hosts attempt to control viral 
dissemination by generating a diverse set of antibodies toward various CMV proteins, 
such as pp65, pp150, gB, gH, and immediate early (IE)-1
51
. The presence of CMV-
specific antibodies are used to diagnose CMV infection and researchers often apply anti-
CMV IgG levels as surrogate markers of CMV infection control
52
. 
Evidence for antibody-mediated viral control can be seen in the context of 
congenital transmission. There is approximately a 40% chance of a fetus becoming 
infected with CMV if the mother develops primary infection during pregnancy, however, 
if the mother transfers CMV-specific IgG antibodies across the placenta, the fetus is less 
likely to become infected
47,53
. Many studies have shown that treatment with CMV-
specific hyperimmune globulin reduces congenital transmission compared to those treated 
with a placebo
54,55
.  
       1.2.1.2 Cellular Immunity 
In addition to humoral immunity, a strong CMV-specific T cell response emerges 
and is maintained, even in the absence of detectable viremia
36
. CMV-specific CD4
+
 and 
CD8
+
 T cell populations commonly occupy ~10% of the entire T cell repertoire, which is 
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an incredibly high percentage considering the overall diversity of the repertoire and 
number of pathogens constantly challenging the human immune system
56
. In more 
extreme cases of memory inflation, the CD8
+ 
effector memory T cell compartment alone 
can reach up to 30% of total CD8
+
 T cells in circulation
52
. These T cell populations 
mostly target the immunodominant proteins pp65 and IE-1
56
. Researchers are currently 
debating whether viral reactivations are the underlying cause of this highly expanded T 
cell population, which is both cytotoxic and produces high levels of IFN-γ and TNF-α 
upon activation
57
. Memory inflation is characterized by the emergence of CMV-specific 
CD8
+
 effector memory T cells which lack CD28, a costimulatory molecule and express 
CD57. These two features in combination denote terminal differentiation and define a 
more phenotypically mature and pro-inflammatory effector memory T cell population
52
. 
CD4
+
 T cells also dedicate a large portion of their resources to CMV control, however, in 
comparison to the fraction of CMV-specific CD8
+
 T cells, their response is generally 
much less extravagant
52
.  
The innate immune response to CMV infection is also dramatic. A specific 
population of differentiated NK cells is uniquely associated with CMV infection (see 
section 1.2.3). However, unlike the expanded T cell population that emerges in CMV 
infection, the lack of CMV-specific receptors on NK cells obscures the driving forces 
behind the expansion and maintenance of this population.  
1.2.3 CMV & Innate Immunity 
        Pattern recognition receptors, such as toll-like receptor 2 (TLR-2) on fibroblasts, 
are among the first to signal CMV invasion. TLR-2 recognizes CMV surface 
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glycoproteins gB and gH, which activates the nuclear factor kappa-light-chain-enhancer 
of activated B cells (NFκB) pathway and recruits antigen-presenting cells (APCs), 
phagocytes, and NK cells
36,58
. CMV has evolved many immune evasion strategies, one of 
which is an interleukin (IL)-10 viral homologue (vIL-10), which mimics the anti-
inflammatory properties of IL-10
36,59
. This immune evasion strategy operates by reducing 
the effector NK cell pool in rhesus macaques, providing evidence for the crucial role of 
NK cells in CMV defense
60
. The interaction between CMV and host NK cells is highly 
complex and is still quite poorly understood. Although NK cells have the capacity to 
control CMV, the reverse appears to hold true, as CMV can leave a lasting mark on host 
immune cell populations.  
A striking example of how CMV infection can dramatically shape the host 
immune system is seen in the  high proportion of peripheral blood NK cells expressing 
the activating receptor NKG2C, compared to CMV-negative individuals
61
. Previous 
reports describe a “dose effect” with regards to the copy number of NKG2C, wherein the 
highest numbers of circulating NKG2C
+
 NK cells are present in NKG2C
+/+
 individuals, 
followed by NKG2C
+/-
 individuals
62,63,64
. This dose effect is more obvious in CMV-
infected hosts because they have larger populations of NK cells expressing NKG2C. 
Despite the associations made between CMV infection and an expanded population of 
NKG2C
+
 NK cells, the interactions driving this expansion, such as a CMV-encoded 
ligand for NKG2C, have yet to be elucidated
65
. 
In contrast with the current uncertainty regarding human responses to CMV, the 
interactions driving expansion of murine CMV (mCMV)-specific NK cells are clearly 
defined. The observation that certain strains of mice displayed resistance to mCMV 
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infection led to a breakthrough in the understanding of murine NK cell responses to 
mCMV. BALB/c mice are susceptible to mCMV infection whereas C57BL/6 mice are 
resistant. By genetically analyzing these mice, Brown et al. were able to pinpoint Ly49H, 
a gene encoding an activating receptor found on the surface of murine NK cells, as a 
driver of mCMV resistance
66
. This receptor directly interacts with the mCMV-encoded 
m157 glycoprotein. Ly49H
+
 NK cells expand and persist following primary infection and 
are able to control future encounters with mCMV
67
.  
Researchers have described the CMV-driven NKG2C
+
 NK cell population as 
reminiscent of the murine Ly49H
+
 NK cell population, however, these populations are 
fundamentally quite different
64
. The expression of NKG2C does not provide resistance to 
hCMV infection, as evidenced by the millions of NKG2C-expressing individuals who are 
CMV-positive. Additionally, there is no evidence for a CMV-derived ligand for 
NKG2C
68
.  Despite these differences, NKG2C-expressing NK cells are still thought to 
play a pivotal role in CMV control, and for this reason have been studied extensively. 
1.2.4 Characterization of NKG2C
+
 NK Cells 
NKG2C
+
 NK cells emerge during CMV infection and often express CD57, a 
maturation marker. There are many functional and phenotypical features which describe 
this expanded population. 
      1.2.4.1 Functional Characteristics of NKG2C+ NK Cells 
 NKG2C
+
 NK cells are characterized by enhanced ADCC through CD16
64,69
. This 
population tends to downregulate main activating receptors such as NKp46 and NKp30, 
and as a result, exhibits less effective natural cytotoxicity
64,69
. NKG2C
+
 NK cells also 
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demonstrate upregulated IFN-γ expression through epigenetic remodeling similar to what 
occurs in CMV-specific CD8
+
 T cells
70
. The IFN-γ promoter region is hypomethylated, 
which leads to quicker and more accessible stimulation of IFN-γ production. This enables 
NK cells to adopt adaptive features despite their innate nature and explains the increased 
production of IFN-γ observed in NKG2C+ NK cells from CMV-seropositive donors70. 
      1.2.4.2 KIR Expression on Adaptive NK Cells 
Adaptive NK cells are further characterized by the selective expression of certain 
KIRs
64
. Beziat et al. showed that both activating and inhibitory KIR expression patterns 
were skewed in expanded NKG2C
+
 NK cell populations
71
. They found a selective 
expansion of NKG2C
+
 NK cells expressing the activating receptors KIR2DS2, 2DS4, and 
3DS1. They also found an association between the expansion of inhibitory KIRs if their 
cognate HLA class I ligands were present within the host. Beziat et al. proposed KIR-
mediated NK cell education as a mechanism behind the expansion of licensed self-
specific KIR
+
 NK cells co-expressing NKG2C in CMV-infected hosts
71
. 
      1.2.4.3 LIR-1 Expression on Adaptive NK Cells 
LIR-1 is an inhibitory receptor found on subsets of monocytes, B cells, T cells, 
and NK cells which binds MHC class I molecules (HLA A, B, C and G) as well as the 
CMV-encoded MHC class I homolog, unique long (UL) region protein 18 (UL18)
72,73
. 
UL18 has been shown to bind LIR-1 with one thousand times stronger affinity than the 
MHC class I molecules
12,73
.  
In a cohort of CMV-infected children, researchers observed an increase in the 
percentage of LIR-1
+
 NK cells within the NKG2C-expressing subset. This enrichment of 
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LIR-1
+
 NK cells was not observed among NKG2C
-
 NK cells, and was significantly 
higher than within the subset of NKG2A-expressing NK cells
74
. There are mixed reports 
regarding the action of UL18 on NK cell function, wherein certain publications report 
LIR-1-mediated inhibition of NK cells, while others reveal the opposite
75,76
.  
      1.2.4.4 CD2 Expression on Adaptive NK Cells 
CD2 serves as a co-stimulatory receptor on NK cells and is upregulated on 
adaptive NK cells after in vitro expansion. The interaction between CD2 on NK cells and 
CD58, which is expressed on infected cells, has been proposed as a contributor to 
adaptive NK cell activation. In a co-culture system, the production of IFN-γ and TNF-α 
by adaptive NK cells diminished after blocking with anti-CD2 or anti-CD58 monoclonal 
antibodies
77
. 
      1.2.4.5 Expression of NKG2A & Other Intracellular Proteins on Adaptive NK Cells 
Another stable feature of expanded NKG2C
+
 cells is the absence of NKG2A, and 
downregulation of certain intracellular signaling proteins such as FcεR1γ, spleen tyrosine 
kinase (Syk), promyelocytic leukemia zinc finger (PLZF) and Ewing‟s sarcoma-
associated transcript 2 (Eat-2)
64,78,79
. Schlums et al. observed a substantial downregulation 
of these proteins among CMV-seropositive hosts, primarily within the CD56
dim 
NK cell 
subset
80
. Among these proteins, downregulation of FcεR1γ was the most pronounced80.  
These features (NKG2C
+
 NKG2A
-
 KIR
+ 
LIR-1
+
 FcεR1γ- Syk- Eat-2- IFN-γ+++), 
paired with enhanced ADCC, define the expansion of an adaptive NK cell population 
wherein CMV is thought to be the main driving force. This expansion, as well as the 
expansion of CMV-specific CD8
+
 T cells, is notably more prominent in HIV-infected 
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individuals
81
. Contrary to initial assumptions, these adaptive NK cell features do not 
appear to be restricted to NKG2C-expressing NK cells. This implies that interactions 
involving NKG2C are not necessary in driving this expansion, and that NKG2C-deficient 
NK cell populations also participate in CMV control.  
1.2.5 Characterization of NKG2C
null
 NK Cells 
Miyashita et al. identified the relatively common homozygous deletion of a 16kb 
region of the genome that encompasses the NKG2C gene
82
. Follow up studies, using their 
uniquely designed PCR primers, revealed that up to 1 in 20 individuals have a 
homozygous deletion of the NKG2C gene. Again, many NKG2C
null
 individuals are still 
able to maintain a subclinical CMV infection, even in the case of those co-infected with 
HIV. The maintenance of subclinical infection affirms existence of CMV control 
mechanisms entirely independent of NKG2C expression. 
     1.2.5.1 Functional Characteristics of NKG2C
null
 NK Cells 
In a cohort of NKG2C-deficient Gambian children, researchers found significant 
elevation in the level of anti-CMV IgG from serum samples
83
. This display of heightened 
humoral responses could be a compensatory measure for slight impairment in innate 
control, or more specifically, in the functional capacity of NK cells from NKG2C-
deficient hosts. The same study also demonstrated an attenuation of CD57
+
 NK cell 
generation among NKG2C-deficient children, implying a potential delay in overall NK 
cell maturation
83
. CMV-driven maturation may not be optimal in NKG2C-deficient 
individuals if somehow NKG2C expression drives NK cell maturation as a whole. A 
consensus has yet to be reached on whether there is a phenotypical or functional 
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impairment in the maturation of NK cells from NKG2C-deficient individuals, and even 
less is known within the context of an immunocompromised host. 
      1.2.5.2 KIR Expression on NKG2C
null
 NK Cells 
Specific constellations of NK cell receptors have been proposed as alternative 
methods of CMV control
17,84, 85
. KIRs are grouped into haplotypes A or B. In the context 
of solid organ transplantation, the presence of a group B (predominantly activating) 
haplotype has been associated with a reduced risk of CMV reactivation
17
. Furthermore, a 
protective effect has been demonstrated wherein individuals with more than five 
activating KIRs, or the simultaneous expression of both KIR2DS2 and 2DS4, have a 
reduced risk of CMV infection
84
. In a cleverly designed study by Chiesa et al., the 
transplantation of cord blood from an NKG2C
null
 donor resulted in a population of 
CD56
dim
 NKG2A
-
 activating KIR
+
 NK cells that were able to degranulate, kill targets, and 
release IFN-γ via stimulation through activating KIRs85. This phenotype is similar to the 
mature NKG2C-expressing NK cell population which is associated with CMV infection, 
and implies the potential role of activating KIRs as a substitute for NKG2C in driving the 
expansion of adaptive NK cells. 
      1.2.5.3 CD2, LIR-1 & FcεR1ү Expression on NKG2Cnull NK Cells 
A research group based out of the Karolinska Institutet investigated NKG2C 
deletion in the context of CMV infection within the largest reported cohort of NKG2C-
deficient individuals (n=60). Their results suggested a role for CD2 as “signal 2” in the 
activation of ADCC among differentiated NK cells by boosting the CD16 signaling 
cascade
86
. CD2 is present on both T and NK cells and serves as a co-stimulatory molecule 
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on NK cells specifically. Liu et al. found that the observed upregulation of CD2 on 
NKG2C
null
 NK cells resulted in the synergistic induction, alongside CD16, of the 
mitogen-activated protein (MAP) kinase and the mammalian target of rapamycin complex 
(mTORC) pathways
86
. Another group brought forth similar findings by showing that 
blocking CD2 or CD58 resulted in diminished antibody-mediated NK cell activation
77
. 
There is little knowledge with regard to NK cell expression of LIR-1 or CD2 
within HIV/CMV co-infected individuals lacking the NKG2C gene. The phenotype of 
NK cells from NKG2C
null 
hosts is an important clue to understanding how adaptive NK 
cells control CMV infection. In a study by Makwana et al., researchers found that the 
most functionally active cells, in terms of CD107a and TNF-α induction, were FcεR1γ- 
LIR-1
+
 NKG2C
-
 NK cells
87
. These results contrast with the popular assumption that 
NKG2C
+
 NK cells selectively display enhanced ADCC functionality. Ultimately, our 
research aims to understand whether NK cells from NKG2C
null
 hosts are as efficient in 
their functional role.  
As the literature suggests, NKG2C appears to be dispensable in the case of overall 
CMV control, however, alternate routes of CMV-driven NK cell maturation are yet to be 
elucidated. Healthy individuals do not form the ideal cohort to decipher if and how 
NKG2C
null
 individuals control CMV infection, as they likely maintain CMV infection 
under tight control. In order to investigate phenotype and potential functional impairment 
of NK cells from NKG2C-deficient hosts we will use a cohort of immunologically 
affected adult individuals as they are the most likely cohort to display altered CMV 
control, highlighting any impairment or compensatory measures. 
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1.2.6 Epidemiology of CMV/HIV Co-infection 
Up to 90 percent of the worldwide population is infected with CMV, depending 
on geographic location and socioeconomic status
88
. The World Health Organization 
(WHO) estimates 36.7 million people are infected with HIV, and certain groups suggest 
nearly all HIV-positive individuals are co-infected with CMV
89,88
. Among our cohort of 
HIV-infected individuals, 84% are CMV-positive, which is slightly above the average 
infection rate among non-HIV-infected individuals, but is significantly lower than a 
typical cohort of HIV-infected individuals wherein reports of up to 100% infection rates 
are common
90
.  
1.3 Overview of Human Immunodeficiency Virus Infection  
Human Immunodeficiency Virus-1 (HIV-1) is a sexually transmitted virus that is 
the result of a cross-species transmission from simian immunodeficiency virus (SIV)-
infected chimpanzees in Southern Africa. Although less common and less pathogenic, 
HIV-2 is endemic in Western Africa and also results in disease
91
. HIV-1 (herein referred 
to as HIV) is the causative agent for acquired immunodeficiency syndrome (AIDS) and 
has resulted in over 35 million deaths, according to the WHO. With the advent of 
antiretroviral therapy (ART), and the resulting decline in progression towards AIDS, 
mortality and morbidity rates are lower in populations with access to ART. This has 
shifted HIV research from focusing on AIDS-related morbidities towards non-AIDS 
defining illnesses, such as cardiovascular and neurological diseases. These non-AIDS 
defining illnesses are typically age-related in the general population, yet appear much 
earlier in HIV-infected individuals on ART. The early appearance of age-related 
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morbidities seen in HIV-infected individuals is likely accelerated by co-infection with 
CMV
92,93
. Understanding the host response to CMV is important for the general 
population, but is especially important for HIV-infected individuals. 
1.3.1 CMV/HIV Co-Infection 
CMV infection can increase susceptibility to HIV infection, enhance untreated 
HIV disease progression towards AIDS, and exacerbate the effects of non-HIV/AIDS 
associated morbidities, even among populations receiving ART
90
. Before researchers 
established CMV as the causative agent behind the emergence of an adaptive NK cell 
population, these adaptive cells were considered an artifact of HIV infection. 
Various studies performed in early 2000 described phenotypic and functional 
features of NK cells within the context of HIV infection. There was an observed 
downregulation of NKp46, NKp30, and NKp44 expression within HIV-infected viremic 
patients, compared to highly active ART (HAART)-treated aviremic patients
94,95
. Another 
group published their findings regarding a switch from NK cells expressing NKG2A to 
NKG2C in HIV-infected patients
96
. NK cell cytotoxicity against K562 cells, which serve 
as natural NK cell targets, was shown to be decreased in HIV-infected viremic patients, 
versus either HIV-infected aviremic individuals or healthy controls
94
.  
The notion that HIV infection was responsible for these specific changes in the 
NK cell repertoire partially changed in 2006 when Guma et al. published a paper 
encouraging researchers to consider CMV serostatus when analyzing phenotypical and 
functional immune characteristics in cases of immunosuppression, such as HIV 
infection
97
. Guma et al. pointed out that many of these associations, such as their findings 
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regarding a switch from NKG2A to NKG2C-expressing NK cells in HIV-infected 
individuals, or others involving NK cell characterization in HIV-infected patients, often 
dissipated when accounting for CMV serostatus. Four years later, a study revealed that 
the switch from NKG2A to NKG2C-expressing NK cells in HIV-infected individuals 
only held true with a concurrent CMV infection
98
. The observed downregulation of 
NKp46 and NKp30 in HIV infection was also subsequently reported as an imprint of 
CMV infection
99
. Finally, less effective natural cytotoxicity is now reported as a hallmark 
of expanded NK cells in CMV infection rather than HIV infection
69
. It is not surprising 
that the expansion of this subset of NK cells was initially identified and labeled as a 
hallmark of HIV infection, as these infections typically coexist in the human host and 
evidence remains that the expansion of NKG2C
+
 NK cells in CMV infection is amplified 
in HIV-infected individuals, compared to HIV-uninfected controls
81
. 
Although many associations have been established between expansion of 
NKG2C
+
 NK cells and CMV/HIV co-infection, little research has been done with a focus 
on the expansion and differentiation of NKG2C
null
 NK cells. To date, no research has 
been published with a focus on NKG2C
null
 NK cells from CMV-infected individuals who 
are also HIV-positive. Certain studies have investigated NKG2C
null
 individuals in CMV 
infection, or NKG2C
null
 individuals in HIV infection, but never a combination of both. 
For these reasons, we selected a cohort of HIV-infected patients for our study, as the 
effects of CMV are amplified in this setting. We hypothesize that any differences in CMV 
control, or in NK cell differentiation, will be amplified in this setting. Additionally, HIV-
infected individuals have larger populations of differentiated NK cells for study purposes.  
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Our study will investigate the effect of NKG2C deletion on phenotypic and 
functional NK cell maturation in the context of HIV-infection by comparing NK cells 
from NKG2C
null
 and NKG2C-expressing hosts, matched for age, CD57
+
 NK cell 
population, and CMV/HIV infection history. We will investigate phenotype using flow 
cytometric analysis of specific NK cell receptors and intracellular proteins (aim 1). 
Functional maturation will be compared after stimulation through CD16 in anti-CD16 
redirected lysis and through natural cytotoxicity assays (aim 2). If those individuals who 
are NKG2C-deficient have lesser differentiated NK cells, or a diminished ability to 
perform effector functions, this could explain the fact that NKG2C-deficient individuals 
have a more difficult time controlling HIV. Conversely, if these individuals have similar 
phenotypic and functional NK cells, this would point to the undoubted existence of 
alternate pathways of CMV-driven NK cell differentiation, aside from NKG2C. 
In summary, our hypothesis is that the lack of NKG2C could impair CMV-driven 
NK cell differentiation into mature effectors with superior ADCC. Therefore, our overall 
objective is to investigate if CMV-driven NK cell differentiation is impaired in HIV-
infected NKG2C
null
 individuals through phenotypical (aim 1) and functional (aim 2) 
analysis. 
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2. Materials and methods 
2.1 Sample Collection and Peripheral Blood Mononuclear Cell Isolation 
 This study received ethical approval from the Health Research Ethics Authority of 
Newfoundland and Labrador. All donors provided informed consent before blood 
collection at the Newfoundland and Labrador Provincial HIV Clinic (St. John‟s, NL, 
Canada), or by a trained phlebotomist at Memorial University‟s Faculty of Medicine (St. 
John‟s, NL, Canada). Blood was collected by forearm venipuncture into acid-citrate 
dextrose-containing vacutainers.  
Peripheral blood mononuclear cells (PBMC) were isolated from freshly drawn 
whole blood by density gradient centrifugation at 400 g using Ficoll-Paque PLUS 
lymphocyte isolation solution (GE Healthcare, Chicago, IL, USA). Briefly, separation of 
PBMC from whole blood involved layering Ficoll-Paque beneath the blood sample. This 
occurred after an initial centrifugation at 400 g and removal of the uppermost plasma-
containing layer using a 5 mL pipette. The remaining blood sample was reconstituted to 
2X the original blood volume with phosphate buffered saline (PBS) (see Table 2.1 for 
preparation of PBS). Next, centrifugation at 400 g for 30 minutes with no brake yielded a 
PBMC-containing layer at the interface between the two resulting phases. The interface 
was removed and washed with PBS containing 1% fetal calf/bovine serum (FCS) (Gibco, 
Gaithersburg, MD, USA). Freshly collected PBMC intended for immediate use were 
resuspended in lymphocyte medium made using Roswell Park Memorial Institute 
(RPMI)-1640 (Gibco) supplemented with 10% FCS, 200 IU/mL penicillin/streptomycin 
(P/S), 1% L-glutamine (all from Gibco), 1% 1 M 4-(2-hydroxyethyl)- 1- 
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Table 2.1 Solution Preparations 
 
Solution Ingredients 
PBS 8 g of NaCl (Sigma-Aldrich) 
0.2 g of KCl (Sigma-Aldrich) 
1.44 g of Na2HPO4 (Sigma-Aldrich) 
0.24 g of KH2PO4 (Sigma-Aldrich) 
1 L dH20 (made to pH 7.4) 
Lysis buffer 10 mM Tris (J. T. Baker, Phillipsburg, NJ, USA) 
10 mM Sodium Chloride (ThermoFisher Scientific) 
1 mM EDTA (Sigma-Aldrich) 
0.5% Sodium dodecyl sulfate (Sigma-Aldrich) 
dH20 (made to pH 8.0) 
TE buffer (m 10 10 mM Tris 
1   1    0.1 mM EDTA  
    In ddH20 (made to pH 8.0) 
Flow buffer 1.04 g EDTA 
0.5% FCS (Gibco) 
1 g Sodium azide (Sigma-Aldrich) 
500 mL PBS (made to pH 7.0-7.2) 
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piperazineethanesulfonic acid (HEPES), and 5.5 x 10
-5 
M 2-mercaptoethanol (both from 
Sigma-Aldrich, St. Louis, MO, USA). Additionally, in order to develop a continuously 
growing cell line which could serve as a primary source of deoxyribonucleic acid (DNA) 
for genome analysis, study participants had their peripheral blood B cells immortalized 
using Epstein-Barr Virus (EBV) as described
101
. Once established, EBV-transformed B 
lymphoblastoid cells were stored in liquid nitrogen until needed.  
2.2 Cryopreservation of PBMC 
If PBMC were not used within 1 day post-isolation, cells were resuspended in 
freezing medium, made using lymphocyte medium supplemented to 20% FCS with 10% 
dimethyl sulfoxide (Sigma-Aldrich), in aliquots of 1.0-2.5 x 10
7
 PBMC/mL. These 
samples were placed in 1.5 mL Nalgene cryotubes (Sigma-Aldrich) for overnight storage 
at -70°C in a Mr. Frosty™ (ThermoFisher Scientific, Waltham, MA, USA) and were 
transferred to liquid nitrogen the following day. Samples remained in liquid nitrogen until 
needed. 
2.3 Thawing PBMC 
Cryogenically frozen PBMC were removed from liquid nitrogen and transported 
on ice to a 37˚C water bath where samples were quickly thawed. After immediate transfer 
to a 15 mL tube containing 10 mL lymphocyte medium (see Section 2.1), samples were 
centrifuged for 5 minutes, decanted, and resuspended in 4 mL lymphocyte medium for 
overnight recovery at 37°C with 5% CO 2. 
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2.4 Identification of NKG2C
null
 Individuals by Flow Cytometry 
PBMC from HIV-infected individuals were separated from whole blood (as 
described in Section 2.1) for analysis by flow cytometry (see Section 2.7 for detailed flow 
cytometry procedures). PBMC were labeled with anti-CD3, -CD56, -CD57, and -NKG2C 
fluorescence-conjugated antibodies (see Table 2.2 for antibody conjugates and suppliers) 
which allowed identification of various cell subsets. Individuals with <1% of NK cells 
(CD3
-
 CD56
+
) expressing NKG2C were identified by analysis with Kaluza Flow 
Cytometry Software 1.2 (Beckman Coulter, Brea, CA, USA). 
2.5 Confirmation of NKG2C
null
 Genotype by Polymerase Chain Reaction 
              Individuals with <1% of NK cells expressing NKG2C were considered “suspect” 
NKG2C
null
 and were genotyped using polymerase chain reaction (PCR) to confirm 
homozygous NKG2C gene deletion. For primers and PCR amplification conditions see 
Section 2.5.2. 
     2.5.1 Deoxyribonucleic Acid Isolation 
Isolation of genomic DNA from cryogenically stored samples was performed by thawing 
EBV-transformed B lymphoblastoid cells and immediately adding them to 10 mL 
lymphocyte medium. Following a centrifugation at 290 g, the supernatant was decanted 
and B cells were resuspended in lymphocyte medium (see Section 2.1) for culture. Once 
viability was over 50%, ~4 million B lymphoblastoid cells were taken for DNA 
extraction, centrifuged for 5 minutes, decanted, and 200 µL lysis buffer (see Table 2.1 for 
preparation of lysis buffer) was added directly to the B cell pellet. Next, the suspension 
was pipetted up and down to ensure adequate mixing before transfer to a 1.5 mL tube. 
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Table 2.2 PCR Cocktail Components 
 
 
a
All products were purchased from Invitrogen 
  
PCR Cocktail
a
 (per 1 reaction)  
PCR buffer 5 µL 
dNTPs (10 µM)  1 µL 
Magnesium Chloride 1.5 µL 
NKG2C or Break Primers 2 µL 
Taq DNA polymerase  0.5 µL 
dH20 38.5 µL 
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After adding 5 µL proteinase K (Invitrogen, Waltham, MA, USA) the suspension was 
vortexed and placed in a 42˚C water bath overnight. 
The following day, 300 µL phenol (Anachemia, Laval, QC, Canada), maintained 
at pH ≥7.8, was added and the suspension was manually shaken for 5 minutes. Next, the 
suspension was centrifuged for 4 minutes at 14,000g. The DNA-containing upper 
aqueous layer was removed and placed in a 1.5 mL tube into which 300 µL 
chloroform:isoamyl alcohol (Baxter Healthcare Corporation, Muskegon, MI, USA, and 
Sigma-Aldrich, respectively) at a ratio of 24:1, was added. This was shaken manually for 
5 minutes and centrifuged for 2 minutes at 14,000 g. The top layer was removed and 
placed in a new 1.5 mL tube. Finally, 750 µL of 100% ethanol (Commercial Alcohols, 
Brampton, ON, Canada) was added, along with 30 µL 3M sodium acetate (NaAc, Sigma-
Aldrich) and the sample was placed at -20˚C overnight. 
On the third day, the sample was centrifuged for 15 minutes at 14,000 g, the upper 
layer was carefully removed using a pipette, and 1 mL 70% ethanol was added. After 
another 15 minute centrifugation at 14,000 g, the supernatant was removed with a pipette 
and the pellet of genomic DNA was air dried for 10 minutes. Finally, DNA was diluted to 
a concentration between 20-200 ng/µL in Tris ethylenediaminetetraacetic acid (EDTA) 
buffer (see Table 2.1 for preparation of tris EDTA [TE] buffer) and DNA content was 
measured using a Nanodrop 1000 spectrophotometer (ThermoFisher Scientific). 
2.5.2 NKG2C PCR 
PCR amplification involved two sets of forward and reverse primers, “NKG2C” 
and “Break”, designed by Miyashita et al. to detect NKG2C deletions82. Break primers 
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(designed to reveal NKG2C deletion) were forward (5‟- 
ACTCGGATTTCTATTTGATGC-3‟) and reverse (5‟- AGTGATGTATAAGAAAAAG-
3‟), and NKG2C primers were forward (5‟-ATCAATTATTGAAATAGGATGC-3‟) and 
reverse (5‟- CGCAAAGTTACAACCATCACCAT-3‟). Stock primer solutions 
(Integrated DNA Technologies, Coralville, IA, USA) were made up in deionized (d)H20 
at a concentration of 6.0 µM and 7.5 µM for NKG2C and Break, respectively. Separate 
PCR cocktails were created for NKG2C and Break primer sets as per Table 2.2. 
        The PCR cocktails were combined with 2 µL DNA (or dH20 for negative control) 
and placed in 0.2 mL thin-walled PCR tubes. DNA from a known heterozygous 
individual (NKG2C
-/+
) was used as a positive control. The PCR conditions were similar to 
those described by Miyashita et al, beginning with a denaturation step at 96˚C for 10 
minutes
82. The following 35 cycles were carried out at 96˚C for 30 seconds 
(denaturation), 45˚C for 30 seconds (annealing), and at 72˚C for 40 seconds (extension). 
This protocol differed from that used by Miyashita et al. in the annealing temperature, 
and that both NKG2C and Break reactions were done under identical conditions. This 
protocol was adapted from Miyashita and adapted such that the conditions could be 
identical without affecting the accuracy of the results. These differences in our protocol 
did not affect the accuracy of our results, as demonstrated by previous members of our 
research group (results not shown). 
Following PCR, samples were subjected to electrophoresis on a 2% agarose gel in 
TE buffer at 110V for 15-20 minutes. DNA bands in the gels were visualized with SYBR 
Safe™ DNA gel stain (Invitrogen) using the Kodak Gel Logic 440 Imager (Kodak, 
Rochester, NY, USA). 
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2.6 Matching NKG2C
null
 Individuals to NKG2C-Expressing Control Group 
Eight individuals were identified as homozygous NKG2C
null
 and, therefore, we 
required a matched control group for comparison purposes. Individuals were matched 
based on age, %CD57
+
 NK cell population, CMV status (based on enzyme-linked 
immunosorbent assay [ELISA] results), CMV-specific CD8
+
 T cell response, and 
duration and severity of HIV disease. These characteristics were obtained from previous 
experiments in the lab (see Table 3.1). 
2.7 Flow Cytometry 
PBMC from healthy controls were used for the optimization of intra- and 
extracellular staining with fluorescence-conjugated antibodies. Extracellular staining of 
resuspended PBMC took place in ~200 µL flow buffer (see Table 2.1 for preparation of 
flow buffer) in the dark at 4˚C for 30 minutes using anti-CD3, -CD56, -CD57, and -
NKG2C antibodies. Following staining, PBMC were washed with flow buffer. 
Intracellular staining was performed using MACS Inside Stain Kit (Miltenyi Biotec, 
Cologne, Germany). Briefly, 250 µL Inside Fix (Miltenyi Biotec) was added, along with 
250 µL flow buffer to form a final concentration of 2 x 10
6
 PBMC/mL. This suspension 
was left to incubate for 20 minutes at room temperature and then washed with 1 mL flow 
buffer. After decanting, 100 µL Inside Perm (Miltenyi Biotec) was added, followed by an 
appropriate volume of antibody (Table 2.3). Antibodies used for intracellular staining 
included anti-FcεR1γ, -IFN-γ, and -TNF-α. Next, the sample was placed in the dark at 
4°C for 10 minutes. Finally, the sample was washed once with 1 mL Inside Perm 
(Miltenyi Biotec) and twice with flow buffer. In preparation for analysis by flow  
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Table 2.3 Antibody-Conjugated Fluorochromes 
 
Antibody 
Specificity 
Fluorochrome 
Conjugate 
Volume Added 
(µL/2.0 x 10
6
 
PBMC) 
Supplier and Clone  
Anti-Human CD3 PE-Cyanine5.5 5 eBioscience
a
 (Clone: 
SK7) 
Anti-Human CD56 APC-Vio770 5 Miltenyi Biotec (Clone: 
REA196) 
Anti-Human CD57 PE-Vio770 5 Miltenyi Biotec (Clone: 
TB03) 
Anti-Human 
NKG2C 
APC 5 R&D Systems
b
 (Clone: 
134591) 
Anti-Human FcεR1γ 
 
FITC 3 Milli-MarkⓇ Millipore 
Sigma
c
 (polyclonal rabbit 
anti-human) 
Anti-Human IFN-γ PE 7.5 eBioscience (Clone: 
4S.B3) 
Anti-Human TNF-α Brilliant Violet 7.5 BioLegend (Clone: 
MAb11) 
a
Waltham, MA, USA 
b 
Minneapolis, MN, USA 
c
Etobicoke, ON, Canada  
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cytometry, cells were fixed in 250 µL of 1% paraformaldehyde (1% PFA) (Sigma-
Aldrich) and stored in the dark at 4°C. 
Analysis was done using Kaluza Flow Cytometry Software 1.2 (Beckman Coulter, 
Brea, CA, USA) after data acquisition on the MoFlo Astrios EQ flow cytometer 
(Beckman Coulter). 
2.8 NK Cell Stimulations 
To measure general NK cell activation through natural cytotoxicity receptors, the 
MHC class I-deficient human erythromyeloblastoid leukemia K562 cell line (American 
Type Culture Collection (ATCC)Ⓡ #CCL 243™) was incubated with PBMC at a 1:5 
ratio (400,000 K562 cells: 2 million PBMC). Pro-inflammatory cytokines were detected 
post-stimulation by flow cytometry after intracellular cytokine staining. Expression of 
IFN-γ and TNF-α was measured, as their production is a marker of NK cell activation. In 
addition to NK cell activation, cellular cytotoxicity was confirmed with NK cell-mediated 
killing of radioactively-labeled K562 targets by 
51
CRAs (results not shown). 
Alternatively, to measure antibody-dependent NK cell activation in vitro, the anti-CD16 
monoclonal antibody, 3G8 (BioLegend, San Diego, CA, USA), was used at a 
concentration of 1 µg/1 x 10
6
 PBMC. Again, the resulting pro-inflammatory cytokine 
response was measured by flow cytometry following intracellular staining of IFN-γ and 
TNF-α.  
Stimulations with the K562 cell line and the anti-CD16 monoclonal antibody took 
place at a concentration of 2 million PBMC/mL lymphocyte medium. After a one hour 
incubation, Brefeldin A (Sigma-Aldrich) was added to a concentration of 10 µg/mL 
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followed by an additional 15-hour incubation at 37˚C with a 5% carbon dioxide (CO2) 
atmosphere.  
All cell lines used in this project were cultured at 37°C in 5% CO2 in lymphocyte 
medium and maintained at a concentration between 0.2 and 1.0 x 10
6
/mL. 
2.9 Cytotoxicity Assays 
Two models of CD16-mediated NK cell cytotoxicity were investigated in this 
project by 5-hour 
51
CRAs. The first model of ADCC used the C1R-B27 B cell line (a gift 
from Kelly MacDonald, University of Toronto, ON, Canada) coated with anti-HLA class 
I antibodies, which served as NK cell targets. The pan-anti-HLA class I antibodies used in 
this assay were produced by the W6/32 murine B cell hybridoma (a gift from Dr. Sheila 
Drover, Memorial University, St. John‟s, NL, Canada). 
The second assay measured killing of the murine mastocytoma cell line, P815 
(ATCCⓇ TIB-64™) by anti-CD16 redirected lysis using the 3G8 monoclonal antibody. 
P815 cells express fragment crystallizable (Fc) receptors on their cell surface, which 
recognizes the Fc portion of the 3G8 antibody, resulting in exposed CD16-specific 
fragment antigen-binding (Fab) regions able to stimulate NK cells via CD16 and mediate 
P815 cell lysis. See Figure 2.1 for an overview of these stimulations. 
Approximately 1 million target cells were pelleted and labeled with approximately 
100 µCi sodium chromate (Na2
51
CrO4, Perkin-Elmer, Waltham, MA, USA) for 90 
minutes at 37˚C in 5% CO2. Post-labeling, target cells were washed three times with PBS 
supplemented with 1% FCS. The CRAs were performed in duplicate in  
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U-bottom 96-well microtiter plates (BD Biosciences, San Jose, CA, USA) with an 
effector to target ratio of 50:1 for both the C1R and P815 assays. 
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Figure 2.1 NK Cell Cytotoxicity Assays 
NK cells kill 
51
Chromium-labeled target P815 cells through crosslinking mediated by 
anti-CD16 antibodies in an anti-CD16 redirected lysis assay [A]. NK cell-mediated 
ADCC was modeled using anti-HLA class I-coated 
51
Chromium-labeled C1R cells [B]. 
  
= Murine Fc Receptor 
 
51
Cr-P815 Cell 
51
Cr-C1R-B27 Cell 
NK Cell 
NK Cell 
= 3G8 (anti-CD16) = W6/32 (anti-HLA class I) 
  
  
= Human Fc Receptor 
A        
     Redirected-ADCC
B     
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The cytotoxicity measured in these assays was mediated by the antibodies which 
cross link effectors (NK cells) to their 
51
Chromium-labeled target cells. P815 cells were 
plated with 12 doubling dilutions of 3G8 antibody at an initial concentration of 100 
ng/mL. C1R cells were plated with 6 doubling dilutions of the W6/32 supernatant, which 
was at an initial concentration of 1000 ng/mL. A “no-antibody control” was also used for 
each cell line, wherein a matched volume of lymphocyte medium was added. Dilutions of 
the anti-CD16 and anti-HLA class I antibodies allowed for the calculation of half-
maximal effective concentrations (EC50).   
Each well contained 200 µL of [antibody-containing]-lymphocyte medium, 50 µL 
target cells (at a concentration of 100,000 target cells/mL), as well as 50 µL PBMC (at a 
concentration of 5,000,000/mL). The maximum release well contained 250 µL of 1 N  
hydrochloric acid along with 5,000 
51
Chromium-labeled target cells. Finally, the 
minimum release well contained 250 µL lymphocyte medium and 5,000 target cells.  
After 5-hour incubation, 100 µL of sample from each well was removed and placed in 
kimble tubes (ThermoFisher Scientific) containing 50 µL bleach. These samples were 
analysed using the Wallac 1480 Wizard Gamma Counter (Perkin Elmer) which provides 
percent lysis as an output. Percent lysis was calculated as follows: 
% lysis =     
(                            )
  (              –             )
 
2.10 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software (GraphPad 
Software, La Jolla, CA, USA). Inter-group comparisons were tested using the Mann-
Whitney U test when results were not normally distributed. If the results were normally 
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distributed, an unpaired student‟s t-test was performed. Normal distribution was 
determined using the D'Agostino-Pearson omnibus test, Shapiro-Wilk test, and the 
Kolmogorov-Smirnov test. Results were considered statistically significant when  
P ≤ 0.05. 
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3. Results 
3.1 Identification of NKG2C
null
 subjects  
3.1.1 Rationale  
 NK cells expressing NKG2C selectively expand following CMV infection. This 
NK cell subset is associated with a differentiated phenotype including expression of 
CD57 and loss of FcεR1γ. Expansion of these differentiated NK cells is exaggerated in 
HIV infection compared to uninfected controls
81
. Additionally, absolute lack of NKG2C 
expression affects susceptibility to HIV infection and disease progression which may be a 
result of compromised NK cell function
97
. NKG2C expression could be partially 
responsible for driving the expansion of differentiated NK cells that display enhanced 
ADCC compared to undifferentiated NK cells which lack these phenotypic markers. For 
this reason, we chose to compare phenotypic NK cell differentiation between HIV-
infected NKG2C
null
 donors and a group of NKG2C-expressing matched donors to 
investigate any variance in differentiation potential associated with the absence of 
NKG2C. An HIV/CMV co-infected cohort serves as an ideal setting for our investigation, 
as it is most likely to reveal any functional discrepancies between NK cells from 
NKG2C
null
 and NKG2C-expressing individuals.   
3.1.2 Identifying NKG2C
null
 Individuals 
Individuals with <1% of their NK cells (CD3- CD56+) expressing NKG2C by 
flow cytometry following extracellular staining for anti-NKG2C and anti-CD57 were 
categorized as “suspect” NKG2Cnull individuals (see Figure 3.1.1). Suspect NKG2Cnull 
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Figure 3.1.1 Identification of Suspect NKG2C
null
 Individuals by Flow Cytometry 
HIV/CMV co-infected individuals typically have an expanded population of NKG2C
+
 
NK cells (right), whereas NKG2C
null
 individuals lack this expansion (left).  PBMC were 
isolated from whole blood donor samples and stained using anti-CD3, CD56, CD57, and 
NKG2C fluorescence-conjugated antibodies for analysis by flow cytometry. NK cells 
(CD3+ CD56-) were gated on for analysis of NKG2C and CD57 expression. 
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individuals were genotyped using NKG2C- and NKG2C deletion-specific primers 
designed by Miyashita et al.
82
. Genotypic analysis included two sets of PCR, one which 
identified the presence of the NKG2C gene (wild type NKG2C) and another which 
identified its absence by amplification of a segment brought into proximity by the 
deletion of a segment of DNA including the coding sequence for NKG2C (NKG2C 
deletion) (see Figure 3.1.2). A combination of these tests allowed determination of 
NKG2C genotype (NKG2C
-/-
, NKG2C
-/+
, or NKG2C
+/+
). We identified 8 homozygous 
null (NKG2C
-/-
) individuals in our study cohort of HIV-infected individuals. All were co-
infected with CMV (see Figure 3.1.3). 
3.1.3 Assigning an NKG2C-Expressing Matched Group 
All donors were assigned identification numbers upon entry into the study. 
NKG2C
null
 individuals were matched to HIV-infected NKG2C-expressing controls based 
primarily on age, %CD57
+
 NK cell population identified by flow cytometry, and anti-
CMV IgG responses measured by ELISA. Other parameters considered were duration of 
HIV infection, nadir CD4
+
 T cell count (cells/mm
3 
peripheral blood) and anti-CMV CD8
+
 
T cell responses identified as IFN-γ-expressing CD8+ T cells post-stimulation with 
overlapping CMV peptides from immunodominant pp65 and IE-1 proteins (see Table 3.1 
for NKG2C
null
 and NKG2C-expressing participant characteristics). This resulted in 8 
NKG2C
null
 male subjects being matched to 1 female and 7 male NKG2C-expressing 
controls based on these parameters. The one female included was the closest match 
available in our cohort (See Table 3.1). There was no significant difference between 
groups with regard to matching parameters (data not shown, Mann-Whitney U test, ns). 
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Figure 3.1.2 Description of PCR Amplifications 
Wild type NKG2C PCR amplifications involved a common 362-base pair fragment 
within the NKG2C gene (primer sites shown in red). NKG2C deletions were identified 
using primer sets which only allow for amplification of a 411-base pair fragment if the 
NKG2C gene is absent from the genome. These primers straddled either side of NKG2C, 
therefore, if NKG2C was present the sequence would be too long to be amplified by 
standard PCR. Scissors indicate deletion sites of the NKG2C gene as occurs in NKG2C
null 
individuals. 
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Figure 3.1.3 Confirmation of NKG2C
null
 Status by PCR 
 
An example NKG2C
null
 individual (Donor 1) showed a band indicating amplification 
within the NKG2C deletion PCR while lacking a band in the wild type NKG2C 
amplification. The heterozygous positive control expressed a band in each region 
(NKG2C
-/+
).  
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Table 3.1 NKG2C
null
 and Matched Group Characteristics 
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21 M 54 20 1.8 6.7 6 138 F 52 18.7 0.8 0.2 147 
28 M 51 24 2.1 11.2 0 78 M 47 24 1.4 4.5 32 
192 M 58 65 1.3 18.3 120 201 M 58 61.1 0.8 4.4 95 
237 M 62 56 1.2 11.4 480 196 M 60 58.7 1.0 14.9 63 
245 M 56 55 1.3 6.3 390 209 M 55 51 1.8 0.2 276 
259 M 35 42 1.0 1.4 323 264 M 34 39 0.8 0.7 660 
270 M 38 31 0.9 1.5 480 174 M 34 32 0.9 0.8 380 
294 M 47 48 1.1 8.1 558 229 M 46 50 1.3 2.3 264 
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a
Null and matched group patient identification number 
b
Anti-CMV IgG responses against CMV AD169-infected MRC-5 cell lysate were 
measured using an ELISA with patient plasma diluted 1:500 (OD=optical density) 
c
Detection of CMV-specific CD8
+
 T cell responses was performed in a 5-hour stimulation 
with overlapping CMV peptides from the immunodominant pp65 and IE-1 proteins, 
followed by intracellular staining for IFN-γ+ CD8+ T cells 
d
Lowest recorded CD4
+
 T cell count (cells/mm
3 
peripheral blood) 
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3.2 Comparison of NK Cell Population Size and Phenotype between NKG2C
null 
and 
NKG2C-Expressing Matched Groups 
3.2.1 Rationale  
Exact mechanisms of NK cell-mediated herpesvirus control remain unclear, 
however, some studies directly implicate NK cells in control of CMV infection. For 
example, an individual devoid of NK cells suffered severe recurrent herpesvirus 
infections, including CMV infection
102
. Furthermore, an individual lacking T cells 
displayed a decrease in CMV viral load concurrent with the emergence of an expanded 
NK cell population homologous to the differentiated NK cell population with enhanced 
ADCC that emerges in chronic CMV infection
103
. This population is marked by the 
expression of CD57 [and NKG2C] and is often accompanied by the loss of FcεR1γ and 
NKG2A. CMV is the only virus that dramatically shapes the host NK cell population in 
such a profound fashion, and this shaping is further amplified in HIV infection
72,81
. For 
these reasons, NK cell constitution and phenotypic differentiation are of particular interest 
in the context of CMV and HIV infection. This is an optimal setting to investigate the role 
of NKG2C. 
3.2.2 Comparison of Percent NK Cells within the Total Lymphocyte 
Population between Groups 
The first way we compared NKG2C
null
 and NKG2C-expressing groups was by 
measuring the overall proportion of NK cells (CD3
-
 CD56
+
) within the lymphocyte 
population (%NK cells/total lymphocytes, see Figure 3.2.1 for gating strategy).  
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Figure 3.2.1 Natural Killer Cell Gating Strategy 
PBMC were isolated from whole blood and stained with anti-CD3, CD56, and CD57 
(extracellular) and anti-FcεR1γ (intracellular) fluorescence-conjugated antibodies for 
analysis by flow cytometry (see Table 2.2 for list of antibody-conjugated fluorochromes 
and their concentrations). This representative gating strategy begins with total PBMC 
(Plot 1) and the lymphocyte population is encircled in [A]. Plot 2 reveals lymphocyte 
expression of CD3 and CD56. Quadrant B-/+ encompasses NK cells (CD3- CD56
+
). Plot 
3 characterizes NK cell expression of CD57 and FcεR1γ. Quadrant C-/+ encompasses 
mature (CD57
+
) NK cells which have lost expression of FcεR1γ. Plots were generated 
using Kaluza Flow Cytometry Software version 1.2. 
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Our results were normally distributed, therefore, we compared groups using a Student‟s t-
test and reported mean values with a 95% CI. The mean NK cell population was 8.7%, 
95% CI [4.8, 12.6] and 11.2%, 95% CI [6.7, 15.7] of total PBMC for the NKG2C
null 
and 
matched donor group, respectively (Figure 3.2.2). There was no significant difference in 
NK cell population sizes between groups (Student‟s t-test, ns). Therefore, in this setting, 
it appears that NKG2C expression or lack thereof has no obvious effect on NK cell 
numbers.  
3.2.3 Comparison of FcεR1γ & CD57 Expression between Groups 
Loss of FcεR1γ from NK cells is associated with more potent ADCC and is more 
common among mature (CD57
+
) NK cells
79,104,105
. First, we confirmed that both groups 
had similar populations of mature NK cells (Figure 3.2.3A). Next, we measured the 
extent of FcεR1γ loss from the overall (Figure 3.2.3B) and mature (Figure 3.2.3C) NK 
cell populations.  
PBMC were isolated from whole blood and labeled for analysis by flow 
cytometry. Our results in Figure 3.2.3A are normally distributed and reveal similar 
CD57
+
 NK cell populations between groups, wherein 62.3%, 95% CI [47.4, 77.1] of 
NKG2C
null
 NK cells expressed CD57, compared to 57.7%, 95% CI [49.9, 65.6] in the 
matched group. There was no significant difference between groups with regard to CD57 
expression (Student‟s t-test, ns). Figure 3.2.3B depicts a broad range of FcεR1γ- NK cells 
from participants in both groups, which are normally distributed and, therefore, reported  
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Figure 3.2.2 NK Cell Population in NKG2C
null
 and Matched Groups 
NK cell (CD3
-
 CD56
+
) frequency represented as percent of total lymphocyte population. 
PBMC were stained with anti-CD3 and CD56 fluorescence-conjugated antibodies for 
analysis by flow cytometry. Data was generated by gating on quadrant B
-/+
 as shown in 
Figure 3.2.1. Results are displayed as mean values with a 95% CI (Student‟s t-test, ns). 
 
 
 
 
 
 
 
  
ns 
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Figure 3.2.3 Loss of FcεR1γ Among NKG2Cnull and Matched Groups 
CD57
+
 NK cells were measured as a percent of total NK cells and data were generated by 
gating on quadrants C
-/+
 and C
+/+
 as shown in Figure 3.2.1. Results are displayed as mean 
values with a 95% CI (Student‟s t-test, ns) [A]. FcεR1γ- NK cells were measured as a 
percent of total NK cells for both groups and data was generated by gating on quadrants 
C
-/+
 and C
-/-
 as shown in Figure 3.2.1. Results are displayed as mean values with a 95% 
CI (Student‟s t-test, ns) [B]. FcεR1γ-  NK cells were measured as a percent of mature 
(CD57
+
) NK cells and data was generated by gating on quadrant C
-/+ 
as shown in Figure 
3.2.1. Results are displayed as mean values with a 95% CI (Student‟s t-test, ns) [C]. 
PBMC were stained with anti-CD3, -CD56, -CD57 and FcεR1γ fluorescence-conjugated 
antibodies for analysis by flow cytometry after separation from whole blood samples 
[Panels A-C]. 
  
ns ns ns 
A B C 
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as mean [95% CI] values. 38.7%, 95% CI [17.8, 59.5] of NK cells from the NKG2C
null
 
group lost FcεR1γ expression compared to 31.9%, 95% CI [20.6, 43.1] in the matched 
group. There was no significant difference in mean FcεR1γ- NK cell values between 
groups (Student‟s t-test, ns). Data in Figure 3.2.3C also followed a normal distribution, 
and contrary to current literature, there was no enhancement of FcεR1γ- NK cells in 
mature NK cell populations
79
. 29.7%, 95% CI [8.0, 51.4] of mature NK cells from the 
NKG2C
null
 group lost expression of FcεR1γ, compared to 21.0%, 95% CI [7.7, 34.3] in 
the matched group (Student‟s t-test, ns). Together these phenotypic data suggest 
equivalent phenotypic NK cell differentiation regardless of NKG2C genotype and lack of 
FcεR1γ- NK cell enrichments among mature NK populations in both groups.  
3.3 NK Cell Cytokine Responses to Stimulation (K562 and 3G8) 
3.3.1 Rationale 
Data presented in section 3.2 showed no significant difference in NK cell 
population size or degree of phenotypic maturation, marked by CD57 expression and loss 
of FcεR1γ, between NKG2Cnull and NKG2C-expressing groups. In this section, we 
investigated whether the observed phenotypic equivalence translated into a similar 
capacity for NK cell activation between groups. To this end, we measured pro-
inflammatory cytokine expression, specifically TNF-α and IFN-γ expression, as markers 
of NK cell activation in response to stimulation. 
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3.3.2 NK Cell Cytokine Production in Response to NCR Stimulation (K562) 
The first stimulation we tested served as a baseline measurement of general NK 
cell cytotoxicity. NK cell activation was measured against erythromyeloblastoid leukemia 
K562 cells, which serve as classical NK cell targets by activation through NCRs in the 
absence of inhibition through HLA class I receptors. Both groups responded by 
expressing equivalent amounts of IFN-γ and TNF-α post-stimulation with K562 cells 
(Figure 3.3.1A and B, respectively). These data are not normally distributed, therefore, 
results are reported as median values followed by interquartile range (IQR). NKG2C
null
 
median IFN-γ expression following exposure to K562 cells was 3.3%, (IQR=1.7-4.2) 
whereas the median expression of IFN-γ among the matched group was 0.9%, IQR=0.4-
4.4. There was no significant difference between groups (Mann-Whitney test, ns).  
TNF-α expression was normally distributed and therefore reported as mean values 
with a 95% CI. Mean TNF-α expression within the NKG2Cnull group was 3.3%, 95% CI 
[0.9, 5.7], compared to 3.1%, 95% CI [1.7, 4.5] in the matched group. Again, there was 
no significant difference between groups (Student‟s t-test, ns). These data show that NK 
cells from both groups were equally competent in their general activation, as measured by 
cytokine production in response to stimulation through NCRs by K562 cells. 
3.3.3 NK Cell Cytokine Production in Response to CD16 Stimulation (3G8) 
Our next goal was to measure NK cell activation through CD16 since 
differentiated NK cells are reportedly better at ADCC. We investigated the relative 
strength of NK cell activation from either group to direct stimulation through CD16 using 
the 3G8 (anti-CD16) monoclonal antibody. The results obtained in these 16-hour assays 
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are displayed in Figure 3.3.2. Our results suggest equivalency between groups in pro-
inflammatory cytokine response to 3G8 antibody-mediated stimulation, as measured by 
IFN-γ (Figure 3.3.2A) and TNF-α expression (Figure 3.3.2B).  
The data in Figure 3.3.2A and B are normally distributed, therefore, statistical 
analysis was performed using Student‟s t-tests.  Mean NKG2Cnull donor group NK cell 
expression of IFN-γ following 3G8 stimulation is 11.0%, 95% CI [5.4, 16.7], compared to 
9.4%, 95% CI [4.6, 14.3] in the matched group. Mean TNF-α+ NK cells, reported in 
Figure 3.3.2B, is 8.7%, 95% CI [3.2, 14.6] among NKG2C
null
 donors and 12.2%, 95% CI 
[4.2, 20] in the matched group. There was no significant difference between groups in 
IFN-γ or TNF-α expression in response to 3G8 stimulation (Student‟s t-test, ns). These 
data show that both groups are equivalent in their capacity for CD16-mediated activation 
by 3G8 stimulation and that mean NK responses to stimulation through CD16 are notably 
stronger than through NCRs by K562 cells (Figure 3.3.1 vs Figure 3.3.2). 
3.4 Measuring NK Cell Cytotoxicity in Models of ADCC 
3.4.1 Rationale 
Thus far we have observed equivalency between groups in NK cell population 
size, phenotype and pro-inflammatory cytokine responses to stimulation through NCRs 
(K562) and CD16 (3G8). To extend these findings, we measured NK cell cytotoxicity 
against antibody-treated cell lines in 5-hour 
51
Chromium release assays involving 
redirected and classical ADCC (refer to Figure 2.1A & B, respectively).  
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Figure 3.3.1 Pro-Inflammatory Cytokine Responses to K562 Stimulation 
PBMC (2 x 10
6
/mL) from NKG2C
null
 and NKG2C-expressing individuals were isolated 
and incubated with K562 cells at a ratio of 2 million PBMC: 400,000 K562 cells for 16 
hours at 37˚C in a 5% CO2 atmosphere (Brefeldin A was added after 1 hour). Post-
stimulation, PBMC were labeled with fluorescence-conjugated antibodies to identify NK 
cells expressing IFN-γ [A] and TNF-α [B]. There was no significant difference between 
groups in median expression of IFN-γ (Mann-Whitney test, ns) or mean expression of 
TNF-α (Student‟s t-test, ns) among NK cells between groups. 
A 
B 
ns 
ns 
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Figure 3.3.2 Pro-Inflammatory Cytokine Responses to 3G8 Stimulation 
PBMC (2 x 10
6
/mL) from NKG2C
null
 and NKG2C-expressing individuals were isolated 
and incubated with the 3G8 monoclonal antibody at a concentration of 1 µg/1 x 10
6
 
PBMC for 16 hours at 37˚C in a 5% CO2 atmosphere (Brefeldin A was added after 1 
hour). Post-stimulation, PBMC were labeled with fluorescence-conjugated antibodies to 
identify NK cells expressing IFN-γ [A] and TNF-α [B]. Results are shown as mean values 
with 95% CI (Student‟s t-test, ns). 
A 
B 
ns 
ns 
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3.4.2 NK Cell Cytotoxicity against Antibody-Coated P815 and C1R Cell Lines 
NK cells from NKG2C
null 
and NKG2C-expressing groups were equivalent in their 
ability to lyse antibody-coated target cells in models of ADCC and anti-CD16 redirected 
lysis. Data are not normally distributed in either assay. There was no significant 
difference between the NKG2C
null
 and matched group in their capacity to mediate anti-
CD16 redirected lysis of 
51
Chromium-labeled P815 cells at the highest concentration of 
3G8 antibody (Mann-Whitney U test, ns). NKG2Cnull donor group median killing of P815 
cells was 20.7%, 95% CI [5.2, 29.1] whereas the matched group was 10.4%, 95% CI [2.6, 
32.0] (see Figure 3.4.1A).   
We found no significant difference between groups in their capacity for lysis of 
51
Chromium-labeled C1R cells coated with the highest concentration of W6-32 antibody 
(Mann-Whitney U test, ns). NKG2Cnull donor median killing of C1Rs was 28.1%, 95% CI 
[15.0, 37.3] compared to matched group killing of 18.2%, 95% CI [19.5, 30.6] (see Figure 
3.4.1B).   
These data indicate equivalence between groups in their capacity for ADCC and 
anti-CD16 redirected lysis regardless of NKG2C expression, however, this applies only to 
stimulations wherein target cells are coated with a saturated concentration of antibody. 
Additionally, both groups appeared to display greater effector function against C1Rs 
(ADCC) relative to stimulation through CD16 by Fc receptor-expressing P815s (anti-
CD16 redirected lysis), although these results are not statistically significant (see Figure 
3.4.1 B vs A). 
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Figure 3.4.1 
51
Chromium Release Assays at Saturating Ab Concentrations 
PBMC (2.5 x10
5
) were incubated with 
51
Chromium-labeled, anti-CD16-coated P815 cells 
[A] or 
51
Chromium-labeled, anti-HLA class I-coated C1R-B57 cells [B] at an effector to 
target ratio of 50:1. Percent lysis was calculated as follows:   
    
(                            )
  (              –              )
 
A 
B 
 
ns 
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3.4.3 NK Cell Sensitivity to Triggering Through CD16 (3G8) and W6/32 
(C1R) 
We reasoned that although both groups displayed equivalent capacity for ADCC 
and anti-CD16 redirected lysis at a saturated concentration of cross-linking antibody, 
there could be differences in sensitivity related to differentiation and maturation in the 
two groups. For example, heightened sensitivity to triggering through CD16 could 
increase target cell killing capacity at lower concentrations of antibody (3G8 or W6/32). 
To investigate differential sensitivity to triggering via CD16 between groups we 
performed doubling dilutions of 3G8 and W6/32 antibodies. Figure 3.4.2 displays a 
representative example of killing over various antibody titrations against P815 [A] and 
C1R [B] cell lines in the assays previously described in Section 2.9. 
In order to convey the similarity we observed between groups in their sensitivity 
to triggering through CD16 in both assays, despite variability in absolute levels of killing, 
we normalized our results (see Figures 3.4.3 and 3.4.4). The EC50, defined as the amount 
of antibody required to elicit a half maximal response, was calculated for both groups. 
NK cell-mediated ADCC followed a similar pattern in both groups. 
W6/32 antibody began at a concentration of 1000 ng/mL and doubling dilutions 
were performed 6 times, resulting in a minimum concentration of 31.25 ng/mL. The 4
th
 
dilution of W6/32 resulted in the EC50 for both the NKG2C
null
 group and matched group 
(Figure 3.4.3). This dilution is equivalent to a concentration of 125 ng/mL W6/32 
antibody. 
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3G8 antibody started at a maximum concentration of 100 ng/mL and doubling 
dilutions were performed 12 times to a final concentration of 0.05 ng/mL. We chose to 
perform additional dilutions with 3G8 because it elicited a stronger pro-inflammatory 
response than W6/32-coated C1Rs at lower concentrations (data not shown). This may be 
due to a higher affinity of 3G8 compared to W6/32 antibodies with donor CD16 
receptors. The mean EC50 from the NKG2C
null
 group and the NKG2C-expressing group 
was at the 7.4 and 7.5
th
 dilution of 3G8, respectively (Figure 3.4.4). These dilutions are 
equivalent to ~1.2 ng/mL W6/32.  
These data suggest equivalent sensitivity to triggering through CD16 between 
NKG2C
null
 and NKG2C-expressing groups as seen through highly similar EC50 values. 
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Figure 3.4.2 Representative Ab Dilution Assays 
Representative examples of donor responses throughout titrations of 3G8 and W6/32 
antibodies in 5-hour 
51
CRAs. PBMC (2.5 x10
5
) were incubated with 
51
Chromium-labeled, 
anti-CD16 (3G8)-coated P815 cells at antibody concentrations ranging from 0.05-100 
ng/mL [A]. PBMC were incubated with 
51
Chromium-labeled, anti-HLA class I (W6/32)-
coated C1R cells at antibody concentrations ranging from 17-1000 ng/mL [B].   
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Figure 3.4.3 W6/31 
51
Chromium Release Assays at Diluted Ab Concentrations  
PBMC (2.5 x10
5
) were incubated with 
51
Chromium-labeled, anti-HLA class I-coated C1R 
cells at antibody concentrations ranging from 17-1000 ng/mL in 5-hour CRAs. EC50 
values were manually calculated for each donor using the concentration resulting in half-
maximal target cell lysis.   
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Figure 3.4.4 P815 
51
Chromium Release Assays at Diluted Ab Concentrations  
PBMC (2.5 x10
5
) were incubated with 
51
Chromium-labeled, anti-CD16-coated P815 cells 
at antibody concentrations ranging from 0.05-100 ng/mL in 5-hour 
51
CRAs. EC50 values 
were manually calculated for each donor from the concentration resulting in half-maximal 
target cell lysis.    
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4. Discussion 
4.1 Summary of Results  
NK cells expressing the activating receptor NKG2C expand following CMV 
infection
104
.  This expanded subset of NK cells is further characterized by expression of 
the maturation marker CD57, loss of FcεR1γ and an enhanced capacity to mediate 
signaling through CD16. The results of this research study provide evidence against 
dependence on NKG2C expression for CMV-driven NK cell differentiation into mature 
effector cells. Our data indicate general equivalency in NK cell population size, 
phenotypic character, cytokine induction and cytotoxic function between NKG2C
null
 and 
NKG2C-expressing donors co-infected with CMV and HIV. 
More specifically, phenotypic NK cell maturation, as measured by the expression 
of CD57 and loss of FcεR1γ, occurred to a similar extent in both groups. The phenotypic 
similarities observed between groups extended to functional equivalency in terms of 
cytokine induction, wherein NKG2C
null
 donors mounted equivalent IFN-γ and TNF-α 
responses to triggering through CD16 (3G8 antibody stimulation) or NCRs (K562 
stimulation). Finally, NK cells from both groups were equally capable of, and equally 
sensitive to ADCC against 
51
Chromium-labeled targets cells (anti-CD16 redirected lysis 
of P815 or ADCC against antibody-coated C1R cell lines) in the presence of saturating or 
limiting antibody concentrations (3G8 or W6/32, respectively). These data indicate 
general equivalency in CMV-driven NK cell differentiation, independent of NKG2C 
expression. 
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Considering the association between NKG2C expression and CMV-driven NK 
cell differentiation, a logical question to pose is whether NKG2C is required for CMV-
driven NK cell differentiation
85,104
. To answer this question, our investigation details 
whether NK cells from NKG2C
null
 individuals can mediate comparable differentiation to 
that observed among NKG2C-expressing individuals. In the context of primary HIV 
infection, homozygosity for NKG2C
(+/+)
 is protective in reducing susceptibility to HIV 
infection and is also protective against disease progression
106
. We reasoned that without 
NKG2C, which appears to mark potent effector cells and diminished risk of HIV 
infection and disease progression, NK cells may not mirror the same phenotypic 
differentiation in the context of CMV infection
106
.  
Our investigation began by comparing absolute NK cell population size between 
groups to exclude the possibility of differential absolute NK cell numbers affecting 
overall NK function and complicating comparison between study groups. We measured 
average NK cell populations among NKG2C
null
 and NKG2C-expressing groups as 8.7% 
and 11.2% of total lymphocytes, respectively, with no significant difference between 
groups. The NK cell population fractions among our cohort were slightly reduced 
compared to healthy controls, wherein NK cells typically comprise 10-15% of total 
lymphocytes. However, reduced NK cell (CD16
+
 CD56
dim
) fractions are typical of HIV 
infection
107
. After controlling for NK cell population size between groups, we proceeded 
to investigate phenotypic characteristics of NK cell differentiation between groups. 
There are estimated to be between 6,000 and 30,000 NK cell subsets per 
individual, each likely bearing a slightly different functional capacity
108
. Infection with 
CMV drives the expansion of a phenotypically distinct NK cell subset which can expand 
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to take up a large proportion of the overall NK cell population. As previously stated, 
CD57 is preferentially expressed on NKG2C
+
 NK cells expanded in CMV infection, and 
FcεR1γ is lost81,78,109. Although there are other markers of this expanded NK cell 
population, such as loss of NKG2A and signaling molecules including PLZF, SYK and 
Eat-2, we chose to characterize NKG2C
null
 NK cell differentiation based solely on 
expression of CD57 and loss of FcεR1γ79,85. CD57 is a well-known surface marker 
associated with NK cell maturation and FcεR1γ is initially associated with the CD16 
receptor that appears to increase in activity on differentiated NK cells.  
We observed no significant difference in NK cell expression of CD57 or in loss of 
FcεR1γ between groups. Our results complement those from a recent study, which also 
reported similar NK cell phenotypes between NKG2C
null
 and NKG2C-expressing 
groups
86
. These findings suggest that there is at least redundancy in NKG2C expression 
for driving NK cell differentiation in response to CMV infection. 
Although studies often do not compare FcεR1γ expression among various NK cell 
subsets, multiple groups have reported accumulation of FcεR1γ- NK cells among mature 
(CD57
+
) NK cell subsets in CMV infection
78,81,109
. Our results are discordant with these 
reports in that we observed a slightly decreased fraction of FcεR1γ- NK cells among 
mature populations (results not shown). We speculate that FcεR1γ can be lost in response 
to various stimuli such as stimulation with 3G8, even in the absence of CMV infection. 
This could explain why we did not observe an accumulation of FcεR1γ- cells among 
mature (CMV-driven) NK cells.  
In summary, speculation that NKG2C gene deletion may affect phenotypic NK 
cell differentiation was not supported by our results, which suggest highly similar CMV-
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driven phenotypic NK cell differentiation between NKG2C
null   
and NKG2C expressing 
groups. Next, we compared NK cell function between groups.  
We chose to measure IFN-γ expression in response to direct stimulation through 
CD16 using the monoclonal antibody, 3G8. Differentiated NK cells upregulate IFN-γ 
expression in response to stimulation through CD16 more readily than undifferentiated, or 
naïve NK cells
70
. This has been attributed to demethylation of CpG motifs in conserved 
non-coding sequences of the IFN-γ gene region, leading to elevated gene expression70. 
Any differences in CMV-driven NK cell differentiation towards enhanced ADCC or 
antibody-dependent cytokine release should be highlighted in this assay. We also 
included a baseline measure of NK cell function involving incubation with K562 cells, 
which cause NK cell activation through NCRs, modeling natural cytotoxicity. A second 
marker of NK cell activation, TNF-α, was added in both of these sets of experiments to 
broaden analysis of pro-inflammatory responses between groups.  
We anticipated similar cytokine expression in response to NCR stimulation 
between groups, as there is no evidence that NKG2C expression affects NK cell capacity 
to mediate natural cytotoxicity. Conversely, we suspected NK cells from NKG2C
null 
individuals might display diminished cytokine expression in response to CD16 
stimulation, as differentiated NK cells, which typically express NKG2C, respond more 
robustly to stimulation through CD16
70
.  
Our results again indicated equivalency between groups in terms of cytokine 
expression in response to stimulation through NCRs. This validates our selection of a 
matched group in terms of general NK cell function. Contrary to our second expectation, 
both groups were also equivalent in terms of activation through CD16. These results 
 - 67 - 
support findings published in 2016 by Liu et al., which reported similar epigenetic 
remodeling of the IFNG promoter in NKG2C
null
 healthy donors, resulting in heightened 
IFN- γ responses following infection with CMV86. 
Although these assays do not allow interaction between NKG2C and its ligand, 
we conclude that general CMV-related differentiation into effectors with heightened pro-
inflammatory cytokine production in response to stimulation through CD16 occurs in 
NKG2C
null 
individuals. In agreement with most current literature, NK cells from both 
groups responded more robustly to stimulation through CD16 compared to stimulation 
through NCRs
24
. Indeed, average IFN-γ and TNF-α expression from either group in 
response to K562 stimulation was only ~5% of NK cells compared to ~10% of NK cells 
post-stimulation with 3G8. 
Of note, when we compared cytokine responses to stimulation via CD16 across 
various NK cell subsets, the CD57
+
 NK cell subset expressed the highest amount of IFN-
γ (data not shown), irrespective of NKG2C expression. This finding was unexpected, as 
most groups report NKG2C
+
 NK cells as the most robust responders to stimulation 
through CD16
61
. However, our findings are in line with a study by Makwana et al. which 
excluded NKG2C as a marker of the most highly activated NK cells in response to 
stimulation (in terms of CD107a expression)
87. Both Makwana‟s and our findings 
constitute further evidence of redundancy to NKG2C expression in driving expansion of 
NK cells with heightened cytokine responses.  
Next, we chose to test whether NK cell-mediated cytotoxic function was similar 
between groups. Indeed, we found that ADCC and anti-CD16 redirected lysis was 
equivalent between groups at a saturating concentration of antibody. Despite the inability 
 - 68 - 
of NKG2C to interact with its ligand in these CMV-independent assays using CMV-
infected donor samples, we conclude that a lack of NKG2C expression does not affect 
general NK cell phenotypic differentiation or capacity to mediate target cell lysis through 
CD16. At this point we considered the effect of saturating antibody concentrations and 
questioned whether NKG2C absence during NK cell differentiation into mature effectors 
could more subtly affect the development of NK cell sensitivity to triggering through 
CD16. To this end, we carried out twelve (3G8 assays) and six (C1R assays) doubling 
dilutions of our sensitizing antibodies to observe cytotoxic responses over a broad range 
of concentrations.  
These cytotoxicity assays were normalized to the maximum amount of killing 
observed for each individual. The maximum amount of killing did not always occur at the 
highest concentration of antibody, which was likely a manifestation of the prozone effect 
(a poorly understood phenomenon in which inaccurately low responses are observed at 
high antibody concentrations due to interference or other unknown issues). Indeed, 
numerous donors displayed the highest amount of target cell killing in the anti-CD16 
redirected lysis assay at the 2
nd
 or 3
rd
 doubling dilution of antibody. We chose to 
normalize our results by assigning 100% lysis as the maximum amount of killing reported 
for each donor at any antibody concentration. Certain donor NK cells did not lyse target 
cells, regardless of the presence of antibodies and these results (3 NKG2C
null
 and 4 
matched donors) were excluded from our analysis of EC50 values. Genetic background 
and/or chronic infection with HIV and CMV may contribute to weak or impaired NK cell 
responses. These results visually depict the extent of overlap in responses between 
groups, despite not being statistically significant due to the low number of donors in each 
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group. The antibody dilution producing a half maximal response (EC50) was calculated 
from raw data for each individual and our results indicated no significant difference in 
EC50 values between groups. This finalized our assessment of NKG2C
null
 NK cells as 
equivalent in phenotype, cytokine induction, and sensitivity to triggering through CD16 
in comparison to their NKG2C-expressing matched counterparts in a CMV-independent 
assay system setting.  
As with most human research, there were limitations to our study. Our analysis 
focused solely on equivalency in phenotype and general function, however, our findings 
do not demonstrate equivalency in a CMV-specific assay setting. This could be a relevant 
issue as CMV-encoded UL40 stabilizes expression of HLA-E on CMV-infected cells 
which, in concert with NKG2C expression on NK cells, may synergize with CD16 
triggering to evoke greater cytotoxic function (ADCC) than observed in our assays. To 
address this limitation, we are developing a CMV-specific 
51
Chromium release assay 
(described in section 4.2), however, further optimization is required for sensitive 
comparison of CMV-specific NK cell ADCC function between our two study groups. 
The participants in our study were recruited through the Newfoundland and 
Labrador Provincial HIV Clinic and despite a relatively small sample size (n=8 out of 160 
donors), this reflects the global distribution of NKG2C
null
 individuals, wherein 5% of 
individuals carry a homozygous deletion of NKG2C
82
.  We emphasize that our study was 
solely concerned with HIV-infected individuals. The setting of HIV infection made our 
study more feasible because it amplifies CMV-driven NK cell differentiation compared to 
HIV-uninfected controls
81
. In other words, HIV infection serves as a magnifying glass by 
way of exaggerating the expansion of differentiated NK cells for analysis.   
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In addition, lack of NKG2C has deleterious effects in HIV infection, therefore, an 
HIV-infected study cohort is logical to investigate the impact of NKG2C absence on NK 
cell differentiation, especially considering the nearly universal rates of CMV co-
infection
90
. Within this specific setting, our study revealed no disadvantage among 
NKG2C
null
 individuals in terms of CMV-driven NK cell differentiation, suggesting that 
NK cell differentiation does not underlie the observed advantage of NKG2C-expressing 
individuals in HIV infection.  
Both HIV infection itself and the ART regimens used to treat HIV infection affect 
general NK cell phenotype and function
95,97,107,110
. For example, in aviremic HIV 
infection the potency of NK cell-mediated ADCC decreases due to reduced expression of 
CD16
110
. Additionally, although ART regimens restore CD4
+
 T cell counts and decrease 
viral replication, NK cell function often does not fully recover
95
. For these reasons, our 
findings are not necessarily reflective of NK cell differentiation in the absence of HIV 
infection and a parallel study including HIV-negative donors either supporting or refuting 
the findings of Liu et al. would complement this study. 
Despite these limitations, phenotypic and functional equivalency between the NK 
cells of NKG2C
null
 and NKG2C-expressing donors was demonstrated for multiple 
measures in CMV-independent assays. This equivalence implies existence of NKG2C-
independent routes to CMV-driven NK cell differentiation.  
4.2 Future Directions & Significance 
The absolute necessity for NKG2C in driving NK cell maturation in response to 
CMV infection is clearly not supported by our results. Thus, it is unlikely that failure of 
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NK cells to mature in response to CMV infection is related to the increased sensitivity to 
HIV infection described for the NKG2C
null
 population, unless NKG2C is somehow 
directly involved in mediating an anti-HIV effect.  Our findings add to the body of 
knowledge concerning NK cell maturation in CMV infection and may direct research 
towards uncovering NKG2C-independent routes of maturation. These routes could be 
harnessed to create NK cells with enhanced function against altered cells in settings of 
infection and cancer.  
In fact, research investigating NKG2C-independent pathways to CMV-driven NK 
cell differentiation has already begun. Liu et al. recently published a study including 60 
NKG2C
null
 healthy controls, which reported similar CMV-driven NK cell differentiation 
over various phenotypic and functional parameters
86
. These findings pressed the 
discovery of alternate routes to NK cell differentiation, wherein they identified CD2 as a 
critical receptor in boosting the CD16 signaling cascade among adaptive NK 
cells
86
.  Shortly thereafter, Rolle et al. reported that blocking CD2 in co-culture assays 
severely diminished adaptive NK cell responses
77
.  
Another receptor that has recently been investigated in this setting is LIR-1, as its 
expression is reportedly higher on NK cells in CMV infection compared to CMV-
negative controls
73
. A CMV-encoded MHC I homolog, UL18, binds LIR-1 with much 
higher affinity than its natural ligands
111
. Incubation of PBMC with CMV-AD169-
infected fibroblasts resulted in heightened pro-inflammatory cytokine responses in 
comparison to when a virus with UL18 deleted from the viral genome was used
73
. Thus, it 
appears that interaction between LIR-1 and UL18 results in immune activation in this 
setting. Makwana et al. found that LIR-1
+
 NK cells were the most active subset in terms 
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of CMV-specific ADCC responses in renal transplant recipients
87
. These results are 
especially interesting as LIR-1 is an inhibitory receptor. In line with its inhibitory 
function, but in contrast with the previously mentioned reports, Prod‟homme et al. claim 
that UL18 inhibits LIR-1
+
 NK cells but activates LIR
-
 NK cells
112
. A clear consensus has 
not yet been reached regarding the role of LIR-1 in NK cell differentiation and function.  
The effect of UL18 on CD8
+
 T cell function is also under debate. Most groups 
report UL18-mediated inhibition of LIR-1
+
 CD8
+ 
 T cells, although one group reported 
UL18-mediated activation
111,112,113
. For these reasons, measuring LIR-1 expression on 
NK cells from CMV-infected NKG2C
null
 individuals could prove interesting as LIR-1 
expression is upregulated on NK cells in CMV infection and its function on NK and T 
cells is disputed. We propose that interactions between UL18 and other immune cells, 
such as DCs, may be skewing recent reports and leading to these discrepancies. 
  Activating KIRs have also been proposed as “alternate” drivers of adaptive NK 
cell expansions in CMV infection. Chiesa et al. investigated KIR expression among three 
NKG2C
null
, CMV-infected donors post-allogeneic hematopoetic stem cell transplant and 
found preferential expression of activating KIRs among the most rapidly expanded NK 
cell population during recovery
85
. Beziat et al. analyzed 200 donor “KIR-omes” and 
found preference for the expression of activating KIR2DS4, 2DS2, and 3DS1 among 
CMV-infected healthy hosts, although this cohort was not NKG2C-deficient
71
.  
These results are intriguing, but analyzing the role of KIR expression in driving 
the expansion of adaptive NK cells is incomplete without concurrently genotyping donors 
for HLA class I in order to identify which NK cells have undergone education. Various 
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groups have found that CMV infection drives the expansion of inhibitory KIR
+
 NK cells 
in the presence of their cognate HLA class I ligand
71,112
.  
The reasons for which CD2, LIR-1, and activating or educated KIRs are 
selectively upregulated among differentiated NK cells in CMV infection remain 
undetermined. The CMV-specific assay we have begun optimizing measures NK cell-
mediated cytotoxicity against 
51
Cr-labeled, CMV AD169-infected human lung fibroblast 
(MRC-5) cells after incubation with anti-CMV antibodies. Upon optimization of this 
assay, the addition of anti-CD2, -LIR-1 and -KIR antibodies in blocking assays might 
yield interesting results on relative levels of killing observed between groups. 
Furthermore, phenotyping NK cells post incubation with CMV-infected MRC-5s could 
offer novel insights into the expression patterns of CD2, LIR-1, and KIRs on responding 
NK cells among NKG2C
null
 and matched individuals. Most importantly, the interaction 
between NKG2C and HLA-E is supported in this assay, which could better expose any 
underlying differences in NK cell function between NKG2C
null
 and NKG2C-expressing 
donors. 
There is reason to believe that differentiated NK cells could be harnessed for the 
targeted killing of unhealthy cells in various chronic infections. For example, FcεR1γ- NK 
cells have been associated with improved outcomes in hepatitis C virus (HCV) 
infections
114
. The observed equivalency in FcεR1γ loss among NK cells between groups, 
along with the fact that we have shown that CMV-negative individuals have considerable 
(>5%) FcεR1γ- NK cells (data not shown) begs the question of a mechanism behind its 
loss. This demonstrates that FcεR1γ loss can occur independently of CMV infection and 
independent of NKG2C expression. Various cytokines or stimulation through regulatory 
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receptors could be potential mechanisms behind this intracellular modification, which 
could be harnessed to create NK cells with enhanced effector function. 
Differentiated NK cells are currently being considered for therapeutic purposes 
beyond chronic infections
1
. Similar to HIV infection, cellular transformation is also 
associated with MHC downregulation, which results in T cell evasion, and conversely, in 
NK cell activation.  In recent years, adaptive NK cells have been associated with more 
effective lysis of cancer cells
115
. Indeed, numerous NK cell-based cancer 
immunotherapies are currently under investigation
116,117
. One form of NK cell-mediated 
tumor cell lysis involves ADCC and requires tumor-specific antibodies (mAbs)
118
. 
Differentiated NK cells have inherently superior ADCC, and could be used in concert 
with antigen-specific mAbs to improve killing efficacy in a multitude of settings. 
No other group has characterized NKG2C
null
 NK cells in the context of CMV/HIV 
co-infection. Our results contradict the widespread assumption that NKG2C expression is 
heavily involved in driving NK cell differentiation in CMV infection, as our NKG2C
null
 
donors were equivalent to matched controls in phenotype (aim 1) and function (aim 2). 
NK cells from NKG2C
null
 donors evidently have alternative routes of differentiation and 
this area of research is currently under exploration. Uncovering alternate routes of CMV-
driven NK cell differentiation is critical for understanding novel ways by which we can 
harness these cells for therapeutic purposes in chronic infections and cancer.  
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